Myo-inositol has no beneficial effect on premenstrual dysphoric disorder

Boris Nemets, Bella Talesnick, Haim Belmaker, Joseph Levine

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Inositol, a simple isomer of glucose, which serves as a precursor in the phosphatidyl-inositol (PI) second messenger cycle, was shown to be effective in double-blind, placebo-controlled studies of depression, panic and obsessive compulsive disorders as well as in bulimia. The following study was designed to investigate whether inositol has beneficial effects in another disorder shown to be responsive to SSRIs: premenstrual dysphoric disorder (PMDD). Eleven female patients with PMDD diagnosed according to DSM-IV participated in a cross-over, double-blind, placebo-controlled trial. The active drug was myo-inositol, 12 g daily, whereas placebo was d-glucose administered at the same dose. Each drug was given during the luteal phase only (14 days prior to menses). for each patient treatment alternated between these two drugs for six menstrual cycles. No beneficial effect was demonstrated for inositol over placebo.

Original languageEnglish
Pages (from-to)147-149
Number of pages3
JournalWorld Journal of Biological Psychiatry
Issue number3
StatePublished - 1 Dec 2002
Externally publishedYes


  • myo-inositol
  • premenstrual dysphoric disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Myo-inositol has no beneficial effect on premenstrual dysphoric disorder'. Together they form a unique fingerprint.

Cite this